Data / Drug companies / Epic Pharma, LLC
Epic Pharma, LLC: 204 products in the FDA NDC directory, labeler code 42806
Epic Pharma, LLC (labeler code 42806) lists 204 products in the FDA National Drug Code Directory, covering 72 finished drugs by generic name. By type: 202 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42806
- Products in commercial distribution
- 204
- Packages
- 374
- Finished drugs by generic name
- 72
- Prescription products
- 202
- Over the counter products
- 2
- Controlled substance products
- Schedule II 28, Schedule III 1, Schedule IV 9
- Flagged as original packager
- 195 of 195 products that carry the flag
- Started marketing in the last 12 months
- 7
- Earliest marketing start
- April 19, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 202 | 99% |
| Over the counter monograph drugs | 2 | 1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 202 | 99% |
| Over the counter drugs | 2 | 1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 76 | 37.3% |
| Capsule | 41 | 20.1% |
| Tablet, film coated | 24 | 11.8% |
| Tablet, extended release | 22 | 10.8% |
| Powder, for suspension | 12 | 5.9% |
| Capsule, liquid filled | 5 | 2.5% |
| Capsule, gelatin coated | 5 | 2.5% |
| Tablet, film coated, extended release | 5 | 2.5% |
| Injection, powder, for solution | 3 | 1.5% |
| Granule | 3 | 1.5% |
| Capsule, extended release | 3 | 1.5% |
| Powder | 3 | 1.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Bupropion Hydrochloride SR | 42806-443 | Tablet, extended release | Generic drugs (ANDA) | September 30, 2026 |
| Bupropion Hydrochloride SR | 42806-442 | Tablet, extended release | Generic drugs (ANDA) | September 30, 2026 |
| Bupropion Hydrochloride SR | 42806-441 | Tablet, extended release | Generic drugs (ANDA) | September 30, 2026 |
| Nintedanib | 42806-569 | Capsule | Generic drugs (ANDA) | July 9, 2026 |
| Nintedanib | 42806-568 | Capsule | Generic drugs (ANDA) | July 9, 2026 |
| Calcitriol | 42806-733 | Capsule | Generic drugs (ANDA) | February 27, 2026 |
| Calcitriol | 42806-732 | Capsule | Generic drugs (ANDA) | February 27, 2026 |
| Buspirone Hydrochloride | 42806-833 | Capsule | Generic drugs (ANDA) | March 13, 2025 |
| Buspirone Hydrochloride | 42806-832 | Capsule | Generic drugs (ANDA) | March 13, 2025 |
| Buspirone Hydrochloride | 42806-831 | Capsule | Generic drugs (ANDA) | March 13, 2025 |
| Doxycycline Hyclate | 42806-310 | Tablet, film coated | Generic drugs (ANDA) | March 7, 2025 |
| Metoprolol succinate | 42806-727 | Tablet, extended release | Generic drugs (ANDA) | February 1, 2025 |
| Metoprolol succinate | 42806-726 | Tablet, extended release | Generic drugs (ANDA) | February 1, 2025 |
| Metoprolol succinate | 42806-725 | Tablet, extended release | Generic drugs (ANDA) | February 1, 2025 |
| Metoprolol succinate | 42806-724 | Tablet, extended release | Generic drugs (ANDA) | February 1, 2025 |
| Ivermectin | 42806-017 | Tablet | Generic drugs (ANDA) | December 15, 2024 |
| Nizatidine | 42806-300 | Capsule | Generic drugs (ANDA) | October 25, 2024 |
| Nizatidine | 42806-299 | Capsule | Generic drugs (ANDA) | October 25, 2024 |
| Cyclophosphamide | 42806-903 | Injection, powder, for solution | Generic drugs (ANDA) | June 30, 2024 |
| Cyclophosphamide | 42806-902 | Injection, powder, for solution | Generic drugs (ANDA) | June 30, 2024 |
| Cyclophosphamide | 42806-901 | Injection, powder, for solution | Generic drugs (ANDA) | June 30, 2024 |
| Carbamazepine ER | 42806-276 | Tablet, extended release | Generic drugs (ANDA) | June 3, 2024 |
| Carbamazepine ER | 42806-275 | Tablet, extended release | Generic drugs (ANDA) | June 3, 2024 |
| Carbamazepine ER | 42806-274 | Tablet, extended release | Generic drugs (ANDA) | March 7, 2024 |
| Gabapentin | 42806-657 | Tablet | Generic drugs (ANDA) | February 26, 2024 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.